

TCF25 Antibody (N-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP17279a

Specification

TCF25 Antibody (N-term) - Product Information

Application Primary Accession Other Accession Reactivity Predicted Host Clonality Isotype Calculated MW Antigen Region WB, IF,E <u>O9BO70</u> <u>O8R3L2</u>, <u>NP_055787.1</u>, <u>A0A8I6ASZ5</u> Human Mouse, Rat Rabbit Polyclonal Rabbit IgG 76667 186-215

TCF25 Antibody (N-term) - Additional Information

Gene ID 22980

Other Names Transcription factor 25, TCF-25, Nuclear localized protein 1, TCF25, KIAA1049, NULP1

Target/Specificity

This TCF25 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 186-215 amino acids from the N-terminal region of human TCF25.

Dilution WB~~1:1000 IF~~1:10~50 E~~Use at an assay dependent concentration.

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

TCF25 Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures.

TCF25 Antibody (N-term) - Protein Information

Name TCF25 {ECO:0000303|PubMed:30244831, ECO:0000312|HGNC:HGNC:29181}



Function Component of the ribosome quality control complex (RQC), a ribosome-associated complex that mediates ubiquitination and extraction of incompletely synthesized nascent chains for proteasomal degradation (PubMed:<u>30244831</u>). In the RQC complex, required to promote formation of 'Lys-48'-linked polyubiquitin chains during ubiquitination of incompletely synthesized proteins by LTN1 (PubMed:<u>30244831</u>). May negatively regulate the calcineurin-NFAT signaling cascade by suppressing the activity of transcription factor NFATC4 (By similarity). May play a role in cell death control (By similarity).

Cellular Location

Nucleus. Cytoplasm, cytosol. Note=Mainly nuclear

Tissue Location


In the embryo, widely expressed with highest levels in brain (PubMed:16574069). In the adult, highest expression is found in the heart (PubMed:16574069, PubMed:32805187). Repressed in cardiac tissue of patients with heart failure (at protein level) (PubMed:32805187). mRNA levels in the heart are unchanged in patients with heart failure (PubMed:32805187).

TCF25 Antibody (N-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>


TCF25 Antibody (N-term) - Images



Fluorescent image of A549 cell stained with TCF25 Antibody (N-term)(Cat#AP17279a).A549 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.1%, 10 min), then incubated with TCF25 primary antibody (1:25, 1 h at 37°C). For secondary antibody, Alexa Fluor® 488 conjugated donkey anti-rabbit antibody (green) was used (1:400, 50 min at 37°C).Cytoplasmic actin was counterstained with Alexa Fluor® 555 (red) conjugated Phalloidin (7units/ml, 1 h at



37°C).TCF25 immunoreactivity is localized to Cytoplasm significantly.



TCF25 Antibody (N-term) (Cat. #AP17279a) western blot analysis in CEM cell line lysates (35ug/lane).This demonstrates the TCF25 antibody detected the TCF25 protein (arrow).

TCF25 Antibody (N-term) - Background

TCF25 is a member of the basic helix-loop-helix (bHLH) family of transcription factors that are important in embryonic development (Steen and Lindholm, 2008 [PubMed 18068114]).[supplied by OMIM].

TCF25 Antibody (N-term) - References

Yoshida, T., et al. Int. J. Mol. Med. 25(4):649-656(2010) Oguri, M., et al. Am. J. Hypertens. 23(1):70-77(2010) Venkatesan, K., et al. Nat. Methods 6(1):83-90(2009) Steen, H., et al. Biochem. Biophys. Res. Commun. 366(2):432-437(2008) Cai, Z., et al. Biochem. Biophys. Res. Commun. 343(3):973-981(2006)